2 99% see COA kanbei buy - large image1](https://file.echemi.com/fileManage/upload/goodpicture/20220906/lithium-99-see-coa-kanbei_b20220906093018385.jpg)
2 99% see COA kanbei buy - image1](https://file.echemi.com/fileManage/upload/goodpicture/20220906/s20220906093018251.jpg "[Ru(dmbpy)3](PF6)2 99% see COA kanbei")
2 99% see COA kanbei buy - image2](https://file.echemi.com/fileManage/upload/goodpicture/20220927/s20220927171043785.jpg "[Ru(dmbpy)3](PF6)2 99% see COA kanbei")
2 99% see COA kanbei buy - large image2](https://file.echemi.com/fileManage/upload/goodpicture/20220927/best-price-5-norbornene-2-carboxylic-acid-butyl-ester-99-see-coa-kanbei_b20220927171043067.jpg "[Ru(dmbpy)3](PF6)2 99% see COA kanbei")
[Ru(dmbpy)3](PF6)2 99% see COA kanbei
GMP ISO
83605-44-1
99%
qingdao
kanbei
25kg/bag
2022-08-31
PVC resin,pvc paste resin,melamine
-
Product Description
-
Seller Information
-
DescriptionCertificatesBasic Info
-
Product Name:
4-methyl-2-(4-methylpyridin-2-yl)pyridine;ruthenium(2+);dihexafluorophosphate
Other Name:MFCD28369258;83605-44-1;Tris(4,4'-dimethyl-2,2'-bipyridine)ruthenium(II) hexafluorophosphate, 95%, DMBPY
CAS No.:83605-44-1
Molecular Formula:C36H36F12N6P2Ru
InChIKeys:YTWDDICTMKIOIQ-UHFFFAOYSA-N
Molecular Weight:943.7 g/mol
Exact Mass:944.132847 g/mol
Categories:
Characteristics-
PSA:
77.3 Ų
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
PVC resin,pvc paste resin,melamine
-
Location:
Room 405, Unit 2, Building 1, Taiji Mansion, No. 38, Nanyang Road, Jinshui District, Zhengzhou City, Henan Province
-
Payment Terms:
TT against copy of documents,L/C
-
Average lead Time:
90
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
-
Year of Establishment:
2022
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product